The initial success of the copyright undeniably reshaped the drug landscape, but placing funds in companies primarily reliant on off-patent versions presents a uncertain picture. While early returns were significant, the expiration of patents and the rise of less expensive alternatives have eroded the customer base. Consequently, a thorough analysi